BackSOPHiA Genetics SA Overview
SOPHiA Genetics SA

SOPHiA Genetics SA Target Price

Where could SOPH trade next? Consensus target price: $12.

Get informed when a big investor buys or sells

+ Follow

Share Price

$8.09

Average Target Price

$11.6744.2% upside

3 analysts in the last 4 months

High: $14 | Low: $9

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-05BTIGMark Massaro$911.2% upsideOpen
2026-08-05H.C. WainwrightSwayampakula Ramakanth$1473.1% upsideOpen
2026-07-20H.C. Wainwright$1248.3% upsideOpen
2026-04-15BTIG$81.1% downsideOpen
2026-03-03BTIGMark Massaro$713.5% downsideOpen
2026-01-26Guggenheim$713.5% downsideOpen
2025-03-06BTIG$538.2% downsideOpen
2024-08-07Morgan StanleyTejas Savant$538.2% downsideOpen
2024-06-27GuggenheimSubbu Nambi$625.8% downsideOpen
2023-01-03BTIGMark Massaro$625.8% downsideOpen

SOPHiA Genetics SA (SOPH) FAQ

SOPHiA Genetics SA (SOPH) currently reports a target price of $12. Use the charts on this page to explore SOPHiA Genetics SA's target price history and peer comparisons.

Analysts' average 12-month price target for SOPHiA Genetics SA is $12, about 44.2% upside from the current share price of $8.09. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $12, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for SOPHiA Genetics SA, and consider following SOPH for alerts when major investors trade the stock.

SOPHiA Genetics SA is classified in the Healthcare sector. On target price, it currently shows $12. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SOPH with unrelated industries.